2025年欧洲肿瘤内科学会乳腺癌年会（ESMO BC）将于当地时间5月14日至17日在德国慕尼黑举行。本次大会内容丰富、亮点纷呈，全面覆盖乳腺癌的靶向治疗、内分泌治疗以及免疫治疗等领域，届时将有多项极具影响力的研究成果公布。《肿瘤瞭望》特别对会议即将披露的重要研究内容进行了系统汇总，以飨读者。
编者按：2025年欧洲肿瘤内科学会乳腺癌年会（ESMO BC）将于当地时间5月14日至17日在德国慕尼黑举行。本次大会内容丰富、亮点纷呈，全面覆盖乳腺癌的靶向治疗、内分泌治疗以及免疫治疗等领域，届时将有多项极具影响力的研究成果公布。《肿瘤瞭望》特别对会议即将披露的重要研究内容进行了系统汇总，以飨读者。
Proffered Paper session 1
时间：4月14日
地点：Room 14
主席：Erika P.Hamilton(Nashville，United States of America)，Masakazu Toi(Bunkyo-ku，Japan)
297O-Imlunestrant(Imlu)with or without Abemaciclib(Abema)in Advanced Breast Cancer(ABC):a Subgroup Analysis in CDK4/6 inhibitor(CDK4/6i)-pretreated Patients(pts)from EMBER-3
Imlunestrant（Imlu）联合或不联合阿贝西利（Abema）治疗晚期乳腺癌（ABC）：EMBER-3中接受过CDK4/6抑制剂（CDK4/6i）治疗的患者（pts）的亚组分析
报告时间：16:30-16:42
讲者：Cristina Saura Manich(Barcelona，Spain)
1O-Kinetics and determinants of blood ESR1 mutation under AI and palbociclib in HR+/HER2-metastatic breast cancer patients in the PADA-1 trial.
PADA-1试验中HR+/HER2-转移性乳腺癌患者在AI和哌柏西利治疗下血液ESR1突变的动力学和决定因素
报告时间：16:42-16:54
讲者：François Clément Bidard(Paris，France)
415O-Predictive Factors of Fertility in Patients with Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy in the POSITIVE trial.
在POSITIVE试验中，中断辅助内分泌治疗以尝试妊娠的乳腺癌患者的生育力预测因素
报告时间：17:14-17:26
讲者：Fedro A.Peccatori(Milan，Italy)
416O-Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy(PrBC)in young BRCA carriers
年轻BRCA携带者之前被诊断为妊娠期乳腺癌（PrBC）后再次妊娠的安全性
报告时间：17:26-17:38
讲者：Marta Perachino(Barcelona，Spain)
Mini Oral session 1
日期：4月15日
地点：Room 14
主席：David Cescon(Toronto，ON，Canada)Kevin Punie(Antwerp，Belgium)Charlotte E.Coles(Cambridge，United Kingdom)
298MO-Clinical Activity of Emiltatug Ledadotin(Emi-Le)，a B7-H4-Directed ADC，in Patients with TNBC who Received at Least One Prior Topoisomerase-1 Inhibitor(Topo-1)ADC
Emiltatug Ledadotin（Emi-Le）是B7-H4的ADC，在接受了至少一种拓扑异构酶-1抑制剂（Topo-1）ADC治疗的TNBC患者中的临床活性
报告时间：08:30-08:35
讲者：Erika P.Hamilton(Nashville，United States of America)
299MO-DESTINY-Breast06(DB-06)post-hoc analysis by physician’s choice of chemotherapy(TPC):efficacy and safety of trastuzumab deruxtecan(T-DXd)vs TPC in hormone receptor-positive(HR+)，HER2-low or-ultralow metastatic breast cancer(mBC)
对比T-DXd与TPC在激素受体阳性（HR+）、HER2低或超低转移性乳腺癌（mBC）中的疗效和安全性的DESTINY-Breast06（DB-06）研究医生选择的化疗方案（TPC）事后分析
报告时间：08:35-08:40
讲者：Carlos H.Barrios(Porto Alegre，Brazil)
300MO-Puxitatug samrotecan(P-Sam，AZD8205)in patients(pts)with HR+/HER2-breast cancer(BC):a first-in-human Phase 1/2a dose escalation and expansion study
Puxitatug samrotecan（P-Sam，AZD8205）用于HR+/HER2-乳腺癌（BC）患者：一项首次人体1/2a期剂量递增和扩展研究
报告时间：08:40-08:45
讲者：Richard D.Baird(Cambridge，United Kingdom)
152MO-Post-mastectomy radiation therapy in patients with Human Epidermal Growth Factor Receptor 2(HER2)-positive breast cancer:analysis of the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization(ALTTO)Trial[BIG 2-06/NCCTG N063D(Alliance)]
人表皮生长因子受体2（HER2）阳性乳腺癌患者乳房切除术后放射治疗：辅助拉帕替尼和/或曲妥珠单抗治疗优化（ALTTO）试验[BIG 2-06/NCCTG N063D（Alliance）]的分析
报告时间：09:00-09:05
讲者：Maria Carmen De Santis(Milan，Italy)
153MO-HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer(HYPART):A non-inferiority，open-label，phase III randomized trial.
高危乳腺癌患者1周vs 2周大分割辅助放疗（HYPART）：一项非劣效性、开放标签、3期随机试验
报告时间：09:05-09:10
讲者：Budhi S.Yadav(Chandigarh，India)
267MO-A Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis(INSPiRED 006):An International，Multicenter Analysis
一种用于乳腺剪切波弹性成像的深度学习模型，以改善乳腺癌诊断（INSPiRED 006）：一项国际多中心分析
报告时间：09:10-09:15
讲者：Lie Cai(Heidelberg，Germany)
LBA2-Rates of pathologic complete response after VV1 and cemiplimab(alone and in treatment sequence-strategy)in the neoadjuvant setting:results from the I-SPY 2.2 trial
新辅助治疗中使用VV1（Voyager V1）联合cemiplimab（单独用药和治疗顺序策略）后的病理学完全缓解率：I-SPY 2.2试验的结果
报告时间：09:30-09:35
讲者：Kay Yeung(La Jolla，CA，United States of America)
LBA3-Primary results from EL1SSAR，a prospective phase 3b study of first-line atezolizumab(atezo)plus nab-paclitaxel(nPac)therapy for patients(pts)with PD-L1+advanced triple-negative breast cancer(aTNBC)
EL1SSAR是一项前瞻性3b期研究：将阿替利珠单抗（atezo）联合白蛋白结合型紫杉醇（nPac）一线治疗用于PD-L1+晚期三阴性乳腺癌（aTNBC）患者（pts）。
报告时间：09:35-09:40
讲者：Suzette Delaloge(Villejuif，Cedex，France)
301MO-Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer:BCT1703 DIAmOND
曲美木单抗（tremelimumab）和度伐利尤单抗（durvalumab）联合曲妥珠单抗治疗曲妥珠单抗耐药晚期HER2阳性乳腺癌的主要疗效结果：BCT1703 DIAmOND研究
报告时间：09:40-09:45
讲者：Sherene Loi(Melbourne，Australia)
191MO-Combination of Talimogene Laherparepvec(T-VEC)with Atezolizumab(atezo)in patients(pts)with residual breast cancer(BC)after standard neoadjuvant chemotherapy(NAC):Survival results of the SOLTI-PROMETEO study
Talimogene Laherparepvec（T-VEC）与Atezolizumab（atezo）联合治疗标准新辅助化疗（NAC）后残留乳腺癌（BC）患者：SOLTI-PROMETEO研究的生存结果
报告时间：09:45-09:50
讲者：Tomás Pascual(Barcelona，Spain)
Proffered Paper session 2
日期：5月15日
地点：Room 14
主席：Masakazu Toi(Bunkyo-ku，Japan)Nicholas Turner(London，United Kingdom)
2O-Integrating Tumor Infiltrating Lymphocytes and Nodal Status for Risk Stratification in Patients(pts)with Triple-Negative Breast Cancer(TNBC)and Pathological Complete Response(pCR)after Neoadjuvant Treatment(NAT)
在新辅助治疗（NAT）后达到病理完全缓解（pCR）的三阴性乳腺癌（TNBC）患者（pts）中，结合肿瘤浸润淋巴细胞和淋巴结状态进行风险分层
报告时间：14:00-14:12
讲者：Davide Massa(Padova，Italy)
189O-Ribociclib+endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2-early breast cancer:Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle-trial
瑞波西利+内分泌治疗与SoC化疗在中危HR+/HER2-早期乳腺癌中的比较：III期WSG ADAPTcycle试验新辅助治疗队列的结果
报告时间：14:12-14:24
讲者：Nadia Harbeck(Munich，Germany)
190O-Clinical outcomes in the OPTIMA prelim(Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis)feasibility study.
OPTIMA prelim可行性研究（使用多参数分析对早期乳腺癌进行最佳个体化治疗）的临床结果。
报告时间：14:24-14:36
讲者：Robert C.Stein(London，United Kingdom)
LBA1-Adjuvant pertuzumab or placebo+trastuzumab+chemotherapy(P or Pla+T+CT)in patients(pts)with early HER2-positive operable breast cancer in APHINITY:Final analysis at 11.3 years’median follow-up
APHINITY研究中位随访11.3年时的最终分析：辅助帕妥珠单抗或安慰剂+曲妥珠单抗+化疗（P或Pla+T+CT）在早期HER2阳性可手术乳腺癌患者中的应用
报告时间：15:01-15:13
讲者：Sibylle Loibl(Neu-Isenburg，Germany)
Mini Oral session 2
日期：5月16日
地点：Room 1
主席：Cristina Saura Manich(Barcelona，Spain)François Clément Bidard(Paris，France)Hope S.Rugo(Duarte，CA，United States of America)
192MO-Primary endpoint of ROSALINE:A phase II neoadjuvant study of endocrine therapy(ET)and entrectinib in invasive lobular breast carcinoma(ILBC)
ROSALINE的主要终点：内分泌治疗（ET）和恩曲替尼治疗浸润性小叶乳腺癌（ILBC）的II期新辅助研究
报告时间：08:20-08:25
讲者：Soraia Lobo-Martins(Brussels，Belgium)
3MO-Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial
MATADOR试验中预测早期乳腺癌患者辅助化疗反应的免疫组化生物标志物
报告时间：08:25-08:30
讲者：Mark Opdam(Amsterdam，Netherlands)
4MO-Development and validation of CDKPredX，a novel predictor of response to neoadjuvant endocrine therapy and CDK4/6 inhibitors versus chemotherapy in ER+/HER2-breast cancer:Correlative analysis of the randomized phase 2 PREDIX Luminal B trial
随机2期PREDIX Luminal B试验的相关分析显示：CDKPredX是ER+/HER2-乳腺癌新辅助内分泌治疗和CDK4/6抑制剂与化疗疗效的一个新的预测因子
报告时间：08:30-08:35
讲者：Theodoros Foukakis(Stockholm，Sweden)
417MO-Identifying harmful weight changes and their impact on breast cancer outcomes:insights from the Nurses’Health Studies
识别有害的体重变化及其对乳腺癌结局的影响：来自护士健康研究的见解
报告时间：08:35-08:40
讲者：Sixten Harborg(Aarhus，Denmark)
302MO-Phase I study of iza-bren(BL-B01D1)，an EGFR x HER3 Bispecific Antibody-drug Conjugate(ADC)，in Patients with Locally Advanced or Metastatic Breast Cancer(BC)
iza-bren（BL-B01D1，EGFR x HER3双特异性抗体-药物偶联物，ADC）治疗局部晚期或转移性乳腺癌（BC）患者的1期研究
报告时间：09:00-09:05
讲者：Yiqun Du(Shanghai，China)
303MO-Zanidatamab(Zani)+Chemotherapy(Chemo)for Patients(Pts)With HER2-Expressing Metastatic Breast Cancer(mBC):Final Results of a Phase 1 Trial
Zanidatamab(Zani)+化疗（Chemo）治疗表达HER2的转移性乳腺癌（mBC）患者：1期试验的最终结果
报告时间：09:05-09:10
讲者：Erika P.Hamilton(Nashville，United States of America)
304MO-Tucatinib and trastuzumab for previously treated HER2-mut MBC:final analysis of a phase 2 basket study(SGNTUC-019)
图卡替尼联合曲妥珠单抗用于既往接受过HER2突变治疗的MBC：一项2期篮式研究（sgntucc-019）的最终分析
报告时间：09:10-09:15
讲者：Alicia Okines(London，United Kingdom)
305MO-Phase II trial of T-DM1 and Palbociclib in Metastatic HER2 positive Breast Cancer
T-DM1联合哌柏西利治疗转移性HER2阳性乳腺癌的2期试验
报告时间：09:15-09:20
讲者：Pavani Chalasani(Washington，DC，United States of America)
5MO-Pretreatment Circulating Tumor(ct)DNA Predicts Metastatic Recurrence in Patients(pts)With High-Risk Early Breast Cancer(eBC)Enrolled in the I-SPY 2 Trial
在I-SPY 2试验中，治疗前循环肿瘤（ct）DNA可预测高危早期乳腺癌（eBC）患者的转移性复发
报告时间：09:40-09:45
讲者：Mark Magbanua(San Francisco，CA，United States of America)
6MO-Baseline ctDNA and methylation status as predictors of treatment benefit in the Phase 3 postMONARCH trial of abemaciclib+fulvestrant in advanced breast cancer patients
在晚期乳腺癌患者中，基线ctDNA和甲基化状态作为阿贝西利+氟维司群3期postMONARCH试验治疗获益的预测因素
报告时间：09:45-09:50
讲者：Seth Wander(Boston，MA，United States of America)
193MO-Predictive value of FDG-PET/CT and MRI for neoadjuvant immunotherapy(IO)response in early-stage triple negative breast cancer(eTNBC):exploratory analysis of the phase 2 BELLINI trial
FDG-PET/CT和MRI对早期三阴性乳腺癌（eTNBC）新辅助免疫治疗（IO）反应的预测价值：2期BELLINI试验的探索性分析
报告时间：09:50-09:55
讲者：Gil Awada(Jette，Belgium)
京公网安备 11010502033352号